Novel Therapeutics for Duchenne Muscular Dystrophy, 2018 Market Report - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 27, 2018--The “Novel Therapeutics for Duchenne Muscular Dystrophy” report has been added to ResearchAndMarkets.com’s offering.
This Genetic Technology TOE depicts life sciences trends in therapeutics for Duchenne’s muscular dystrophy. The topics covered range from gene editing approaches to breakthrough muscle-on-a-chip innovations.
Clinical trial analysis of important investigational therapeutics for Duchenne muscular dystrophy is also presented.
The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
Key Topics Covered:
Recent Advances in Development of Novel Therapeutics for Duchenne Muscular DystrophyCRISPR-based Therapeutic in Development for Duchenne Muscular Dystrophy Multiple Treatment Development for Diverse DMD Population Solid Biosciences’ IGNITE DMD Clinical Trial to Resume Muscle-on-a-chip Platform for DMD Target Discovery
Clinical Trial Analysis and Key ContactsClinical Trial Analysis of Important Investigational Therapeutics for Duchenne Muscular Dystophy Key Contacts
For more information about this report visit https://www.researchandmarkets.com/research/f5grgq/novel?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180927005729/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs ,Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/27/2018 12:45 PM/DISC: 09/27/2018 12:45 PM